Coventry University Featured PhD Programmes
University of Kent Featured PhD Programmes
FindA University Ltd Featured PhD Programmes
The Francis Crick Institute Featured PhD Programmes
Cardiff University Featured PhD Programmes

PhD studentship in oncolytic virotherapy and cancer immunology: Establishing a potent immuno-oncolytic virotherapy for colorectal cancer.

This project is no longer listed on and may not be available.

Click here to search for PhD studentship opportunities
  • Full or part time
    Dr A Parker
    Prof A Gallimore
    Dr A Godkin
  • Application Deadline
    No more applications being accepted
  • Funded PhD Project (European/UK Students Only)
    Funded PhD Project (European/UK Students Only)

Project Description

An exciting, fully funded PhD studentship opportunity: working at the interface between oncolytic virotherapy and cancer immunotherapy to develop a refined, tumour targeted “immunovirotherapy” suitable for colorectal cancer treatment.
The Parker lab focusses on developing viruses to treat cancer. Viruses have exciting potential to treat cancer, since they are the only form of therapy that self-amplifies, through replication, within the tumour microenvironment. Furthermore, viruses can be engineered to produce copious amounts of other anti-cancer therapies as a by-product of infection, for example antibodies such as Herceptin, which have added value clinically. However, viruses haven’t evolved as cancer treatments, and in their “untrained” state infect normal cells, causing disease. The Parker lab focuses on undoing these natural means of infection, and “training” viruses to only infect cancer cells.
Research within the Gallimore/Godkin group focusses on development of immunotherapies to fight cancer. Commonly, when cancer develops, it does so because the cancer has developed means to evade detection by the host’s immune cells, which normally recognises cancerous cells, targeting them for destruction. Immunotherapies are medicines that are designed to help re-energise the host immune system to help them detect cancer cells. Recently, the Godkin/Gallimore groups have developed an exciting new immunotherapy - an antibody that binds and inactivates a key immune molecule called Lag3.
In this project, we deploy our respective expertise to develop bespoke, cancer targeted virotherapies overexpressing novel immunotherapies.

Funding Notes

This project is generously funded by Cancer Research Wales. Full UK/EU tuition fees, Doctoral stipend matching UK Research Council National Minimum and a full consumables budget.
The desired intake date is October 2019, although an earlier intake in April or July can be arranged if required by the selected candidate.

Minimum degree classification is upper second class (2i) degree, ideally in a related subject area (e.g. immunology, genetics). Applicants with additional laboratory experience – ideally to Master’s level and/or significant additional lab experience are especially encouraged to apply.


Applicants should provide a full CV (including details of a minimum of 3 potential referees) and a cover letter and personal statement to outline any relevant experience, and their motivation for applying for this position.

In order to be considered you must submit a formal application via Cardiff University’s online application service. (click 'Apply now' at the bottom of this page to be taken to the website.
There is a box at the top right of the page labelled ‘Apply’, please ensure you select the correct ‘Qualification’ (E.g. Doctor of Philosophy), the correct ‘Mode of Study’ (E.g. Full Time) and the correct ‘Start Date’ (E.g. October 2018). This will take you to the application portal.

Related Subjects

FindAPhD. Copyright 2005-2019
All rights reserved.